committed to personalized treatment.
We believe that truly personalized medicine can only exist when the right drug is taken at the right dose.
Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax’s proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians monitor and optimize patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com
Ms. Foster has over 30 years of experience in the diagnostics and medical devices industries. Her extensive experience spans chemistry/immunoassay to molecular diagnostics/biotechnology within organizations ranging from blue-chip corporations (i.e., Johnson & Johnson) to entrepreneur start-ups. She has developed and led dynamic; high-performance teams focused on commercialization and business development strategies and execution. She has been instrumental in market development and successful product launches that include random access immunoassay, molecular analyzers, and diagnostic tests in cardiology, infectious disease, and psychiatry. Ms. Foster has her BBA from St Mary's College, Notre Dame, and MBA from Kellogg School of Management, Northwestern University.
Mr. Esposito was a member of the Board of Directors at Angioblast Systems, Inc. and at Aspect Medical Systems, Inc. prior to their acquisitions. He is a former Trustee and is now Chairman of the Annual Appeal for the Rotch-Jones-Duff House & Garden Museum. He is a member of the Board of Trustees of the New Bedford Symphony Orchestra and a member of the Corporation of MCPHS University (formerly The Massachusetts College of Pharmacy and Health Sciences).
David was a member of the UK Department of Transport expert panel that introduced drug-driving regulation. He is currently a member of the UK government’s Advisory Council on Misuse of Drugs.
Professor Taylor is the Editor-in-Chief of the journal Therapeutic Advances in Psychopharmacology.
Professor Taylor has been the lead author of the Maudsley Prescribing Guidelines since their inception in 1993. The Maudsley Prescribing Guidelines have sold over 300,000 copies in fourteen editions and twelve languages. David has also authored over 350 clinical papers in journals such as the Lancet, BMJ, British Journal of Psychiatry and Journal of Clinical Psychiatry. These papers have been cited over 15,000 times. Professor Taylor has written or edited seven other books and written over twenty book chapters.